2seventy Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of 2seventy Bio Inc (TSVT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: 2seventy Bio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 48M vs 485,818M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+89.7% annualized vs trailing 12 months), vs decelerating (-27.8%) for its tracked peer group.
- Growth: 2seventy Bio Inc generated 84.5% revenue growth year over year in Q1 2025, vs 5.0% for its competitors combined.
- Profitability: Its 2.1% net margin compares with 23.3% for the peer group.
- Peer revenue share: 2seventy Bio Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.24M compares with $0.96M for the peer group (0.2x).
- Structure: 2seventy Bio Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TSVT Sales vs. its Competitors, Q1 2025
2seventy Bio Inc reported revenue growth of 84.46 % year on year in Q1 2025, above its competitors' combined revenue growth of 5.04 %.
With a net margin of 2.10 %, 2seventy Bio Inc reported lower profitability than its competitors (23.27 %).
2seventy Bio Inc generated 0.03 % of the combined sales of its peer group, up from 0.01 % a year earlier.
API endpoints for this dataset
2seventy Bio Inc vs. its Competitors, Q1 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in 2seventy Bio Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across 2seventy Bio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| 2seventy Bio Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (89) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across 2seventy Bio Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 84.5% for 2seventy Bio Inc. 2seventy Bio Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
2seventy Bio Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| 2seventy Bio Inc | No | No | No | Yes |
| Competitors combined (40) | ||||
| High-Confidence Competitors (104) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TSVT Stock Performance relative to its Competitors
TSVT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Immix Biopharma Inc | 282.9% | Outperformed |
| 3 | Longeveron Inc | 282.9% | Outperformed |
| 4 | Organon and Co | 282.9% | Outperformed |
| 5 | Merus N v | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for 2seventy Bio Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of 2seventy Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 2seventy Bio Inc |
267.17 | 48.36 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Astrazeneca Plc |
291,203.66 | 58,739.00 |
| SUBTOTAL | 3,189,736.86 | 485,867.12 |
Sign in to see all competitors of 2seventy Bio Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on 2seventy Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
2seventy Bio Inc's Competitors Named by the Company
Competitive relationships identified from 2seventy Bio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Fulgent Genetics Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Exscientia Plc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Eisai Co., Ltd. | Company report | 85% |
| Atreca inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Tango Therapeutics, Inc. | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Exelixis, Inc. | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Replimune Group Inc | Company report | 85% |
| BMS | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Boehringer Ingelheim AG | Company report | 85% |
| RENB | Company report | 85% |
| Bayer-Schering Pharmaceutical | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Syndax, Inc. | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| APDN | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Perspective Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Longboard Pharmaceuticals Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Aldeyra Therapeutics Inc | Company report | 85% |
| Ideaya Biosciences Inc | Company report | 85% |
| Cogent Biosciences Inc | Company report | 85% |
| Prelude Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| Repare Therapeutics Inc | Company report | 85% |
| Xilio Therapeutics Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Prothena Corporation Public Limited Company | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Celldex Therapeutics inc | Company report | 85% |
| Reunion Neuroscience Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Harpoon Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for 2seventy Bio Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
2seventy Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| 2seventy Bio Inc | Reportable 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
2seventy Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| 2seventy Bio Inc | 267 | 239,431 | -20,257 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,204 | 706,847 | 123,141 |
| PEERS TOTAL | 3,189,470 | 963,949 | 149,800 |
2seventy Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Hutchmed china Limited | CN 74.28 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
2seventy Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in 2seventy Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.2seventy Bio Inc ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | 2seventy Bio Inc | 267 | 0.00 % |
Market cap and industry share for the rest of 2seventy Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-05-12.
2seventy Bio Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.89 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 5.80 % | -6.23 % (avg) | +12.0 pp |
| Capital Intensity (Capex / Revenue) | 0.20 % | 7.58 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
2seventy Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | 30.6x | 15.9x | +14.7x |
| P/B | 0.8x | 4.3x | -3.5x |
| Return on Equity | -1.84 % | industry aggregate | -17.03 % |
| Return on Invested Capital | -9.91 % | -9.83 % (avg) | -0.08 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
2seventy Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | 67.81 % | 9.72 % | -62.28 % |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -25.67 % | -25.60 % | -17.09 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
2seventy Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.20 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on 2seventy Bio Inc's dedicated Suppliers and Customers pages, not here.
2seventy Bio Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
2seventy Bio Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
2seventy Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+89.7% annualized vs trailing 12 months).
Weaknesses
- Return on equity 17.0 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (51.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-27.8% annualized).
Methodology: see Methodology: SWOT Analysis.
2seventy Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| 2seventy Bio Inc | 1.94 | 4.80 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
2seventy Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| 2seventy Bio Inc | Q1 2025 | +84.5 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +9.8 % | -4.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
2seventy Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| 2seventy Bio Inc | Q1 2025 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
2seventy Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| 2seventy Bio Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
2seventy Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| 2seventy Bio Inc | - | 5.52 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Merck and Co Inc | 118.32 | 5.44 |
| Novartis Ag | 22.73 | 5.61 |
| Astrazeneca Plc | 28.51 | 4.96 |
| PEERS AVERAGE | 42.25 | 6.57 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.